- Arch Biopartners Inc. (ARCH) has received approval for revision to the CATCO protocol to include the LSALT Peptide
- Health Canada has issued a ‘No Objection Letter’ for the clinical trial application – amendment to the CATCO team
- LSALT Peptide treats inflammation in the lungs, liver, and kidneys
- CATCO is the controlled study to see the drug’s effects
- It is Arch’s responsibility to supply LSALT drug vials during the trial
- Arch Biopartners Inc. (ARCH) is up 0.54 per cent and is trading at $3.72 per share as of 11:02 a.m. EST
Arch Biopartners Inc. (ARCH) has received approval for a revision to the CATCO protocol to include its lead drug candidate, LSALT Peptide.
Health Canada has issued a ‘No Objection Letter’ for the clinical trial application – amendment to the CATCO team. Dosing of LSALT peptide is expected to begin following final local approval and clinical site preparation.
LSALT Peptide is the company’s lead drug candidate for treating inflammation in the lungs, liver, and kidneys.
CATCO is a controlled study being piloted in approximately 55 hospitals across Canada. Its goal is to find new treatments for patients suffering from the complications caused by COVID-19.
CATCO is supported by the Canadian Network of COVID-19 Clinical Trials Networks which is funded by the Canadian Institutes of Health Research.
Sunnybrook Research Institute (SRI) is the sponsor of the CATCO trial and administers the trial across all sites in Canada.
SRI entered into a collaboration agreement with Arch to use LSALT in a new arm of the CATCO trial.
It is Arch’s responsibility to supply LSALT drug vials during the trial to support the dosing of up to approximately 350 patients.
Arch is a clinical-stage company that is developing a pipeline of new drug candidates to work against inflammation.
Arch Biopartners Inc. (ARCH) is up 0.54 per cent and is trading at $3.72 per share as of 11:02 a.m. EST.
